Mechanism Study of Yangyin Roujin Formula in the Treatment of Fibromyalgia Syndrome

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorJuan Jiao

About this trial

This prospective randomized, double-blind, controlled clinical trial is designed to address the current challenges in the clinical management of fibromyalgia (FM). We adopt Yangyin Roujin Formula, an empirical herbal prescription used in routine clinical practice, to evaluate its comprehensive therapeutic efficacy and safety in FM patients, including alleviating physical pain and common concomitant symptoms, improving physical function, and enhancing quality of life. Serum and fecal samples as well as brain MRI scans will be collected at baseline and after 12 weeks of intervention. The underlying mechanisms of this formula will be explored from multiple dimensions, including serology, gut microbiota-metabolome profiling, and central neuroimaging, so as to clarify the therapeutic advantages of Yangyin Roujin Formula for FM treatment.

Eligibility criteria

Qualifiers

Patients with primary fibromyalgia who met the FM classification criteria established by the American College of Rheumatology in 2016.

TCM syndromes of liver qi stagnation and yin blood insufficiency, or hepatic and renal yin deficiency.

aged 18 years old and above, 75 years old and below.

pain VAS score ≥ 4.

Disqualifiers

patients with cardiovascular and cerebrovascular, liver, kidney and hematopoietic system and other serious primary diseases and thrombotic diseases ; Lactating or pregnant women ; patients with allergy to therapeutic ingredients ; patients with severe pain caused by other diseases ( such as diabetic pain or postherpetic neuralgia ) ; patients who have recently participated in clinical trials of the same indications ; Patients who are male, right-handed, or have contraindications for MRI will not undergo MRI scanning.

Trial design

Treatments tested in this trial

  • Yangyin Roujin Decoction
  • placebo

Treatment groups

60 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Juan Jiao

Lead sponsor

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Sponsor institution